Latest news with #NZZ
DW
3 days ago
- Business
- DW
Child Labor Powering Green Tech – DW – 05/23/2025
Almost 75% of global production comes from the Democratic Republic of Congo - where there are also children toiling away in the mines. Image: NZZ Format Cobalt is a component in batteries for cell phones, EVs and e-bikes, but it's also used in medical technologies and aircraft construction. Around three-quarters of the world's supply of this coveted metal currently comes from the DRC in Central Africa. Kolwezi is known as the country's cobalt capital. Industrial mines, like those operated by Swiss multinational Glencore and Chinese firms, are found here alongside illegal sites where hundreds of thousands of people hack the metal out of the ground with their bare hands. Image: NZZ Format Human rights organizations like Amnesty International and Save the Children estimate that tens of thousands of minors work in these illegal cobalt mines. In protest, activists have repeatedly called for a boycott on cobalt from the DRC. To what extent is child labor a factor in cobalt production today, and what can consumers do to combat it? What about corporate responsibility? Are companies doing enough to ensure the cobalt they're using hasn't been mined by a child? Broadcasting Hours: DW English MON 26.05.2025 – 18:30 UTC MON 26.05.2025 – 23:30 UTC TUE 27.05.2025 – 03:30 UTC TUE 27.05.2025 – 09:15 UTC TUE 27.05.2025 – 12:15 UTC TUE 27.05.2025 – 16:15 UTC TUE 27.05.2025 – 21:15 UTC WED 28.05.2025 – 07:30 UTC WED 28.05.2025 – 10:30 UTC WED 28.05.2025 – 17:30 UTC Lagos UTC +1 | Cape Town UTC +2 | Nairobi UTC +3 Delhi UTC +5,5 | Bangkok UTC +7 | Hong Kong UTC +8 London UTC +1 | Berlin UTC +2 | Moscow UTC +3 San Francisco UTC -7 | Edmonton UTC -6 | New York UTC -4
Yahoo
15-05-2025
- Business
- Yahoo
Trump drug price plan could nix investment, warns Roche
President Donald Trump's plans to dramatically slash drug prices for Americans could make Swiss pharmaceutical giant Roche cancel major investments in the United States, it said Wednesday. Trump signed an executive order Monday aimed at bringing down the notoriously high prescription drug prices paid by US consumers, news that rattled pharmaceutical companies. Swiss newspaper NZZ reported Trump's move could lead Roche to reassess plans it announced just last month to invest $50 billion in the United States over five years. Roche, the world leader in cancer treatments, said in a statement it did not expect Trump's new drugs policy to hurt its business in 2025. "However, should the proposed EO (executive order) go into effect, Roche's ability to fund the significant investments previously announced in the US will be in question," it said. Trump has been pushing foreign firms to invest more in the United States, saying the way to avoid his tariff assault on foreign-made goods is to produce them on US soil instead. Prescription drugs were not targeted in Trump's "Liberation Day" tariff announcements. Still, Roche appeared to take heed with its April investment announcement, which came just after fellow Swiss rival Novartis said it would increase investment in the United States by $23 billion over five years. The United States is a key market for Roche, accounting for more than half its pharmaceutical division's revenues. Roche's US subsidiary Genentech announced a $700-million project Monday to build a new plant in North Carolina, which it says would employ 400 people. noo/jhb/jj Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Iraqi News
15-05-2025
- Business
- Iraqi News
Trump drug price plan could nix investment, warns Roche
Zurich – President Donald Trump's plans to dramatically slash drug prices for Americans could make Swiss pharmaceutical giant Roche cancel major investments in the United States, it said Wednesday. Trump signed an executive order Monday aimed at bringing down the notoriously high prescription drug prices paid by US consumers, news that rattled pharmaceutical companies. Swiss newspaper NZZ reported Trump's move could lead Roche to reassess plans it announced just last month to invest $50 billion in the United States over five years. Roche, the world leader in cancer treatments, said in a statement it did not expect Trump's new drugs policy to hurt its business in 2025. 'However, should the proposed EO (executive order) go into effect, Roche's ability to fund the significant investments previously announced in the US will be in question,' it said. Trump has been pushing foreign firms to invest more in the United States, saying the way to avoid his tariff assault on foreign-made goods is to produce them on US soil instead. Prescription drugs were not targeted in Trump's 'Liberation Day' tariff announcements. Still, Roche appeared to take heed with its April investment announcement, which came just after fellow Swiss rival Novartis said it would increase investment in the United States by $23 billion over five years. The United States is a key market for Roche, accounting for more than half its pharmaceutical division's revenues. Roche's US subsidiary Genentech announced a $700-million project Monday to build a new plant in North Carolina, which it says would employ 400 people.
France 24
14-05-2025
- Business
- France 24
Trump drug price plan could nix investment, warns Roche
Trump signed an executive order Monday aimed at bringing down the notoriously high prescription drug prices paid by US consumers, news that rattled pharmaceutical companies. Swiss newspaper NZZ reported Trump's move could lead Roche to reassess plans it announced just last month to invest $50 billion in the United States over five years. Roche, the world leader in cancer treatments, said in a statement it did not expect Trump's new drugs policy to hurt its business in 2025. "However, should the proposed EO (executive order) go into effect, Roche's ability to fund the significant investments previously announced in the US will be in question," it said. Trump has been pushing foreign firms to invest more in the United States, saying the way to avoid his tariff assault on foreign-made goods is to produce them on US soil instead. Prescription drugs were not targeted in Trump's "Liberation Day" tariff announcements. Still, Roche appeared to take heed with its April investment announcement, which came just after fellow Swiss rival Novartis said it would increase investment in the United States by $23 billion over five years. The United States is a key market for Roche, accounting for more than half its pharmaceutical division's revenues. Roche's US subsidiary Genentech announced a $700-million project Monday to build a new plant in North Carolina, which it says would employ 400 people. © 2025 AFP
Yahoo
12-03-2025
- Health
- Yahoo
Reports: German intel agency collected evidence of Covid-19 lab leak
Germany's BND intelligence agency reportedly gathered plausible evidence that the coronavirus pandemic originated with a laboratory leak in the Chinese city of Wuhan, according to reports by three newspapers on Wednesday. The BND and Germany's Chancellery had asked scientists to examine the evidence over recent months, although the outcome of that assessment was not immediately available, according to reports in the NZZ, Süddeutsche and Die Zeit newspapers. The so-called "lab leak" theory has long been a prominent but controversial explanation for the deadly global pandemic. It posits that the Sars-CoV-2 virus originated from the Wuhan Institute of Virology, which conducted research on coronaviruses, and began spreading through some sort of accident or failure at the lab. The other major theory for the pandemic's origin is that the virus had a purely natural origin, just like the SARS outbreak in 2002-3. Not all researchers involved in the BND round were equally convinced that the virus clearly came from the laboratory, according to the NZZ. Some see the probability of a man-made pandemic from the institute growing steadily, but have not yet wanted to commit themselves. Deputy government spokeswoman Christiane Hoffmann told journalists in Berlin that they had taken note of the reports. However, it was not possible to comment on intelligence findings and activities. She said that the responsible committees of the German parliament, which meet in secret, would be informed in such matters. In January, US President Donald Trump's newly appointed director of the US Central Intelligence Agency (CIA), John Ratcliffe, changed his agency's assessment of the origin of the coronavirus as one of his first official acts.
